Ashley Rogers, MD

Assistant Clinical Professor, Pediatrics-Heme/Onc and Bone Marrow Transplantation


FacultyPhoto
Medical School
  • MD, University of Colorado Denver School of Medicine (2004)
Undergraduate School
  • BA, Dartmouth College (NH) (2000)
Internship
  • University of Colorado (Children's Hospital Colorado) Program (2006)
Residency
  • University of Colorado (Children's Hospital Colorado) Program, Pediatrics (2008)
Fellowships
  • University of Colorado (Children's Hospital Colorado) Program, Pediatric Hematology / Oncology (2011)
Languages
English, Spanish
Department
Pediatrics-Heme/Onc and Bone Marrow Transplantation

Professional Titles

  • Pediatric Hematologist-Oncologist

Recognitions

  • Patient-Family Experience Award for Excellence in Patient Care - 5 Star Award, Patients of Children's Hospital Colorado (2016)
    5 star Award - Awarded for achieving 95% or higher with ratings of greater than or equal to 9/10 on Overall Provider Experience as rated by patients.
  • Patient-Family Experience Award for Excellence in Patient Care - 5 Star Award, Patients of Children's Hospital Colorado (2017)
    5 Star Award - Awarded for achieving 95% or higher with ratings of greater than or equal to 9/10 on Overall Provider Experience as rated by patients.
  • Alpha Omega Alpha Honor Society, Alpha Omega Alpha (2004)
    Medical School Honor Society for top academic performance

Research Interests

Epidemiology and prevention of blood stream infections in patients with Acute Myelogenous Leukemia; Supportive Care in AML and ALL; Advancing treatment options for children with leukemia and lymphoma

Publications

  • Rogers A, Hunger SP. F1000 Medicine review of Pediatric-type nodal follicular lymphoma: an indolent clonal proliferation in children and adults with high proliferation index and no BCL2 rearrangement. Faculty of f1000 Medicine, October 2012. http://f1000.com/717962610.
  • Rogers A, Hunger SP. F1000 Medicine review of Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure vor children with very-high-risk leukemia. Faculty of f1000 Medicine, August 2012. http://f1000.com/717950300.
  • Rogers A, Hunger SP. F1000 Medicine review of Absence of biallelic TCR? deletion predicts induction failure and poorer outcomes in childhood T-cell acute lymphoblastic leukemia. Faculty of f1000 Medicine, Apr 2012. http://f1000.com/14267329.
  • Eisenman K*, Rogers AEJ*, Hunger S. Chemotherapy of Childhood Acute Lymphoblastic Leukemia. Contemporary Management of Childhood Acute Lymphoblastic Leukemia. In press. *Both authors contributed equally
  • Hunger S and Rogers A: F1000Prime Recommendation of [Kaspers GJ et al., J Clin Oncol 2013, 31(5):599-607]. In F1000Prime, 11 Jul 2013; DOI: 10.3410/f.717971500.793479680. F1000Prime.com/717971500#eval793479680
  • Hayley L. Ross, Cathy Lee-Miller, Brian Bagrosky, Ashley E.J. Rogers, " Persistent Fevers in a Neutropenic Patient," Pediatrics in Review. In submission 2014.
  • Eisenman K, Rogers A, Hunger SP. Chemotherapy of childhood acute lymphoblastic leukemia and acute myeloid leukemia. In Contemporary Management of Acute Lymphoblastic Leukemia. Pullarkar V (ed.). Jaypee Brothers Medical Publishers, Dehli, In Press.
  • Rogers A, Hunger SP. F1000 Medicine review of Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the st jude lifetime cohort stud. Faculty of f1000 Medicine, February 2014. http://f1000.com/718402640.
  • Rogers A, Hunger SP. F1000 Medicine review of Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal LLymphoma Study Group IELSG-26 Study. Faculty of f1000 Medicine, July 2014. http://f1000.com/718166534.
  • Ashley E. J. Rogers, MD, Kristen M. Eisenman, MD, Susan A. Dolan, RN MS CIC, Kristin M. Belderson, RN, Jocelyn R. Zauche, RN, Suhong Tong, MS, Joanne M. Hilden, MD, Michael Wang, MD, Kelly W. Maloney, MD, and Samuel R. Dominguez, MD, PhD. Risk Factors for Central Line Associated Blood Stream Infections in Children with Acute Myelogenous Leukemia: A Single Institution Report. ASPHO, May 2015.
  • Hayley L. Ross, M.D., Cathy Lee-Miller, M.D., Brian Bagrosky, M.D., Ashley E.J. Rogers, M.D. Persistent fevers and abdominal pain in a 13-year-old neutropenic patient. Pediatrics in Review. March 2015.Volume 36 No 3, 127-129.
  • Rogers AE, Eisenman KM, Dolan SA, Belderson KM, Zauche JR, Tong S, Gralla J, Hilden JM, Wang M, Maloney KW, Dominguez SR. Risk factors for bacteremia and central line-associated blood stream infections in children with acute myelogenous leukemia: A single-institution report. Pediatr Blood Cancer. 2016 Sep 12. [Epub ahead of print] PubMed PMID: 27616655
  • Ross HL, Lee-Miller C, Bagrosky B, Rogers AE. Case 1: Persistent fevers and abdominal pain in a 13-year-old neutropenic patient. Pediatr Rev. 2015 Mar;36(3):127-9. PubMed PMID: 25733764
  • Keating AK, Kim GK, Jones AE, Donson AM, Ware K, Mulcahy JM, Salzberg DB, Foreman NK, Liang X, Thorburn A, Graham DK. Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity. Mol Cancer Ther. 2010 May;9(5):1298-307. PubMed PMID: 20423999
  • Jones AE, Albano EA, Lovell MA, Hunger SP. Metastatic alveolar rhabdomyosarcoma in multiple endocrine neoplasia type 2A. Pediatr Blood Cancer. 2010 Dec 1;55(6):1213-6. PubMed PMID: 20533522
  • Rogers AE, Le JP, Sather S, Pernu BM, Graham DK, Pierce AM, Keating AK. Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology. Oncogene. 2012 Sep 20;31(38):4171-81. PubMed PMID: 22179835
  • Liang X, Jones A, Giller RH, Swisshelm K, McGavran L, Meltesen L, Carstens B, McGranahan AN, Albano EA. Primary high-grade B-cell lymphoma of the breast with concurrent IGH-BCL2 and MYC-IGL translocations in an adolescent patient. Pediatr Dev Pathol. 2011 Sep-Oct;14(5):402-6. PubMed PMID: 21491965
  • Eisenman K, Rogers A, Hunger SP. Chemotherapy of childhood acute lymphoblastic leukemia and acute myeloid leukemia. InContemporary Management of Acute Lymphoblastic Leukemia. Pullarkat V (ed.). Jaypee Brothers Medical Publishers, New Dehli, 2014. *Both authors contributed equally
  • Rogers AE, Eisenman KM, Dolan SA, Belderson KM, Zauche JR, Tong S, Gralla J, Hilden JM, Wang M, Maloney KW, Dominguez SR. Risk factors for bacteremia and central line-associated blood stream infections in children with acute myelogenous leukemia: A single-institution report. Pediatr Blood Cancer. 2017 Mar;64(3). PubMed PMID: 27616655

Professional Memberships

  • Alpha Omega Alpha, Member
  • American Society of Pediatric Hematology Oncology , Member
  • American Academy of Pediatrics (AAP), Member

Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
13123 East 16th Ave
Aurora, CO 80045
720-777-1234

Hospital Affiliation
  • Children's Hospital Colorado
  • University of Colorado Hospital

Center Affiliations

Specialty Information

Specialties
  • Pediatrics, Board Certification
  • Pediatric Hematology / Oncology, Board Certification
Conditions & Treatments
  • Blood / Lymphatic System - Blood Disorders
  • Child and Teen Health
  • Cancers - Lymphoma
  • Cancers
  • Cancers - Leukemia (Childhood)
  • Cancers - Chemotherapy
  • Blood / Lymphatic System
Clinical Interests
I specialize in caring for children with cancer with a focus in care of children with Acute Lymphoid/Myeloid Leukemia and Non-Hodgkin's Lymphoma. I look forward to meeting with you and your child to help find the best care and treatment for him or her.

Care Philosophy
I strive to give children and their families warm and consistent care, to treat children as I would want my own children to be treated. I believe in meticulous and thorough patient care and in forming a therapeutic alliance with my patients and their families to help children thrive through the challenging journey of illness. I strive to be abreast of the latest clinical knowledge in pediatric oncology and to continue to modify patient care in line with the most promising treatment plans.